Pharmacotherapy of atrial fibrillation.
Atrial fibrillation (AF) remains a widespread health problem and the drugs available for its treatment suffer from several drawbacks, including potentially lethal proarrhythmia, serious non-cardiac toxicity and limited efficacy. The evidence for efficacy of currently available anti-arrhythmic agents for sinus rhythm restoration and maintenance is reviewed, with emphasis on randomised trials when available. The current approach to thromboembolism prophylaxis in AF is summarised.
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.
J
J
Nemec
W K
WK
Shen
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans
D000889:Anti-Arrhythmia Agents; D002317:Cardiovascular Agents